Key Areas of Expertise:
Cancer clinical trials
Cancer-induced bone disease
Professor Robert Coleman is a Professor of Medical Oncology and Director of the CR-UK/YCR Sheffield Cancer Research Centre.
Professor Coleman graduated from Kings College Hospital Medical School, University of London in 1978. Following clinical training in oncology in London and Edinburgh and completion of a research doctorate (MD) in the field of bone metastases, he became senior lecturer and honorary consultant in the newly formed Academic Unit of Clinical Oncology at Weston Park Hospital in 1991. He now leads a large clinical research team and is Director of the Gestational Trophoblastic Diseases Treatment Centre in Sheffield. Since 2011, he has been an Associate Director of the National Cancer Research Network (NCRN). he is the Lead for the new CR-UK / YCR Sheffield Cancer Centre.
Over the years, he has developed a highly successful cancer clinical trials facility, which has both led and participated in a broad range of clinical trials. These have ranged from early phase drug development studies to large phase III randomised trials. As research lead for clinical cancer research he is responsible for running the Cancer Clinical Trials Centre, a purpose built clinical research facility that provides the research infrastructure for the North Trent Cancer Research Network, the Experimental Cancer Medicine Centre, and the breast cancer component of the bone oncology research laboratories within the medical school.
Since the mid 1980s Professor Coleman’s main research interest has been into cancer induced bone disease especially with relevance to breast cancer. His research in this area is internationally recognised and has included a range of clinical aspects of care, the development of bone targeted agents in oncology, evaluation of bone markers in oncology to aid drug development and provide both prognostic and predictive information in the management of metastatic bone disease, and the assessment of adverse effects of cancer treatments on bone health and evaluation of various treatment strategies. He has established a laboratory based translational programme of research into interactions between anticancer agents and bisphosphonates that has identified synergistic interactions that are now being tested in the clinic.
- AZURE Clinical trial of adjuvant bisphosphonates in early breast cancer with translational components
- BISMARK trial of marker directed therapy
- Industry portfolio of studies
- Late Effects of cancer treatment focusing on endocrine and metabolic issues
Professor Rob Coleman MBBS, MD, FRCP (London & Edinburgh) Department of Oncology Cancer Clinical Trials Centre Academic Unit of Clinical Oncology Broomcross Building Weston Park Hospital Sheffield S10 2SJ
Tel: +44 (0)114 226 5213
Fax: +44 (0)114 226 5364
For further information please visit: Clinical Oncology